EF Hutton Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

In a report released today, Michael King from EF Hutton reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONNResearch Report), with a price target of $6.70. The company’s shares closed yesterday at $0.92.

According to TipRanks, King is a 4-star analyst with an average return of 5.3% and a 41.60% success rate. King covers the Healthcare sector, focusing on stocks such as Agenus, Regeneron, and Sonnet BioTherapeutics Holdings.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sonnet BioTherapeutics Holdings with a $6.70 average price target.

See Insiders’ Hot Stocks on TipRanks >>

SONN market cap is currently $18.61M and has a P/E ratio of -0.15.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company that is focused on the development of drugs for the treatment of cancer.

Read More on SONN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More